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2Don’t call it “degenerative!”
Non-rheumatic aortic stenosis has assumed center stage in contemporary cardiology due to the 
aging of the population and the prodigious advances in percutaneous approaches to its treatment. 
Many refer to this disease dismissively as “degenerative.” That term implies an inevitable, 
ineluctably progressive, and inherent process that defies slowing or regressing. Use of the term 
“degenerative” cloaks our ignorance regarding mechanisms, much as do the designations 
“idiopathic” cardiomyopathy or “essential” hypertension. Yet, in step with the remarkable 
advances in addressing the mechanical aspects of aortic stenosis, researchers continue to stride
toward better mechanistic understanding of the pathophysiology of this condition. Rather than 
“degenerative” aortic stenosis, we advocate use of the terms “fibrocalcific” or “sclerocalcific” 
aortic valve disease: nomenclature that captures the hardening of the valve tissue and its 
mineralization. We now recognize a number of active biological mechanisms that pave the 
pathway to alterations in the structure and function of the aortic valve (Figure 1).
New insights into the mechanisms of aortic stenosis
A healthy aortic valve maintains its physiologic functions by means of highly organized tissue 
architecture. The aortic valve leaflets contain three distinct extracellular matrix layers: a 
collagen-rich fibrosa, an elastin-rich ventricularis, and a spongiosa, a middle layer rich in 
glycosaminoglycans (Figure 2A). This tri-laminar structure determines the biomechanical 
properties of the valve leaflets. Disease progression involves simultaneous thickening and 
stiffening of the valve leaflets due to fibrosis and formation of calcific nodules that originate on 
the base of the fibrosa/aortic aspect of the leaflet (Figure 2B). 
The resident cell populations responsible for maintenance of valve homeostasis and structural 
integrity include valvular endothelial cells (VECs) and valvular interstitial cells (VICs). Healthy 
adult cardiac valves contain mostly VICs that resemble quiescent fibroblasts. During disease 
progression, these cells can undergo activation and become myofibroblast–like cells that express 
metalloproteinases (e.g., MMP-1, MMP-2, MMP-9, MMP-13) and pro-inflammatory cytokines 
(e.g., IL-1), mediators that can promote tissue remodeling
1
and fetal valve development.
2
The 
extent of VICs heterogeneity (including progenitor cells,) and how VIC subpopulations might 
contribute to aortic stenosis requires further investigation.
Multiple mechanisms lead to the evolution of the normal to the diseased valve. Two distinct 
forms of calcification predominate in calcific aortic valve disease (CAVD): (1) 
inflammatory/oxidative stress-driven and (2) hyperphosphatemia-related. These processes 
involve distinct mechanisms and may operate simultaneously in the same tissue.
Inflammation and immunity: Newly recognized drivers of aortic stenosis
3In addition to the resident cells, the diseased valve harbors different denizens, including immune 
cells such as macrophages and CD8-positive T lymphocytes, likely recruited through an 
abnormal endothelium. Emerging evidence suggests that these immune cells contribute to the 
formation of osteoclast-like cells, although they remain dysfunctional as they lack calcium 
resorptive activity.
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During the early pro-inflammatory phases of calcification, activated 
macrophages and other inflammatory cells likely drive disease progression through pathological 
matrix remodeling and the release of osteogenic cytokines.
4
TNF- or IL-6 can trigger
biomineralization and osteogenic signaling through activation of bone morphogenetic protein 
family members (BMP) and Wnt signaling. Foci of incipient calcification/microcalcification may 
then activate macrophages and promote a positive calcification-inflammation feedback loop that 
drives disease progression. Indeed, chronic inflammation contributes to valve calcification in 
mice, a phenomenon now established by Fluoride and fluorodeoxyglucose imaging in humans.
5
Generation of reactive oxygen species (ROS) often accompanies inflammation, and has 
particularly pathogenic properties in CAVD.
6
ROS activate osteogenic reprogramming in human 
CAVD and in cultured VICs evident by DNA damage and elevation of the transcriptional factors 
Runx2 and Msx2. Increased intracellular ROS accumulation causes mitochondrial dysfunction in 
type 2 diabetes mellitus and the metabolic syndrome, conditions that both associate with CAVD. 
Therefore, targeting ROS-associated osteogenic signaling cascade provides one potential avenue 
for modifying the progression of aortic stenosis.
Elevated levels of oxidized LDL associate with heightened fibrocalcific responses in aortic 
valvular tissue, possibly through pro-inflammatory pathways that involve Toll-like receptors. 
Strong human genetic evidence implicates Lipoprotein (a) [Lp(a)] as a causal factor in aortic 
stenosis. Lp(a) has many physiological and pathological actions including transport of oxidized 
phospholipids and binding to LDL and very low-density lipoprotein receptors. Lp(a) also 
transports lysophosphatidic acid secreted by VICs and promotes mineralization of aortic valves.
7
In view of the strong association between the LPA gene variant (rs10455872) with the increased 
risk of developing aortic stenosis by >50%, Lp(a)-targeted interventions (including anti-sense 
oligonucleotide and anti-PCSK9 therapies) warrant further exploration in the context of CAVD.
Renal dysfunction, hyperphosphatemia, and uremic toxins also contribute to aortic stenosis
Approximately 50% of individuals with chronic kidney disease (CKD) die from cardiovascular 
complications.
8
In addition to classic risk factors such as age and dyslipidemia, patients with 
CKD have hyperphosphatemia, an independent risk factor for cardiovascular death. Recent 
preclinical studies show that macrophage-derived MMPs or cathepsins degrade elastin fibers,
producing biologically active elastin peptides that can initiate calcification of VICs, which 
together with elevated phosphate concentrations could accelerate valve mineralization. Emerging 
evidence suggests that high serum concentrations of uremic toxins, including indoxyl sulfate, 
increase with the progression of CKD, particularly in patients undergoing hemodialysis. In vitro
4studies using vascular cells further demonstrate that uremic toxins promote cell proliferation, and
inflammatory cytokine and ROS production. In addition, administration of indoxyl sulfate to rats 
induced aortic calcification and fibrosis. 
Microvesicles can contribute to calcification
Elevated extracellular calcium and phosphate, as found in patients with CKD, can induce the 
release of calcifying extracellular vesicles (microvesicles) from cardiovascular cells, including 
macrophages and vascular smooth muscle cells. Calcifying vesicles can carry cargo that 
promotes calcification of neighboring cells and extracellular matrix. The content of extracellular 
vesicles dictates their function. Intracellularly, phosphorylated sortilin transports tissue-
nonspecific alkaline phosphatase, a molecule required for calcification, from the Golgi to the 
intracellular membrane resulting in the formation of calcification-prone vesicles.
9
Upon their
release these vesicles tend to aggregate, merge, nucleate hydroxyapatite, generate 
microcalcifications, and thus foster the formation and growth of advanced calcific nodules.
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Proteomic studies have shown that circulating extracellular vesicles contain multiple mediators 
implicated in cardiovascular calcification (e.g., sortilin, annexins, S100A9, tissue-nonspecific 
alkaline phosphatase, microRNAs, oxidized LDL.) 
Monogenic disorders contribute to cardiovascular calcification 
Bicuspid aortic valve, the most common congenital heart valve disease, occurs in 1-2% of the 
population. A combination of factors, including genetic susceptibility, abnormal mechanical 
forces, and environmental risk likely contributes to the pathobiology and earlier onset of 
symptoms in patients with BAV.
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BAV contributes to 50% of aortic stenosis and associates with 
structural abnormalities of the aortic wall such as aortic aneurysm and aortic dissection. Genetic 
variants may promote abnormal expression of proteins regulating extracellular matrix and alter 
different signal transduction cascades during valvulogenesis. After birth, severe disruption of 
valve structure can create anomalous blood flow, which in turn may alter cell signaling and 
tissue remodeling. Mutations in the Notch signaling pathway associate with BAV.
12
In addition, 
studies indicate that eNOS-deficient mice develop BAV and eNOS‐derived nitric oxide 
modulates the Wnt/Lrp5 pathway, which may mediate aortic valve calcification.
Dipeptidyl peptidase-4: A new link between aortic stenosis and pathways involved in 
diabetes?
In this issue of Circulation Song and colleagues
13
propose a novel mechanism that promotes 
aortic valve calcification, action of the enzyme dipeptidyl peptidase-4 (DPP4), a multifunctional 
enzyme, found in plasma in the catalytically active soluble form and on the surface of many
cells. DDP-4 inhibitors, oral hypoglycemic drugs, enjoy broad use for the treatment of type 2 
diabetes mellitus. The authors found that VEC dysfunction gauged by nitric oxide depletion 
promotes DPP-4 expression in human VICs. DPP-4 in turn induces osteogenic differentiation of 
VICs through increasing degradation of insulin-like growth factor-1 (IGF-1). Hence, the DPP-4-
5IGF-1 axis may mediate VEC-VIC interaction. In vitro, the inhibition of DPP-4 enzymatic 
activity blocked the osteogenic changes in VICs. DPP-4 inhibition reduced calcified lesion 
formation in eNOS-deficient mice and prevented experimental CAVD in rabbits. This study 
underscores again a critical role for the endothelium, particularly eNOS, in the initiation of 
CAVD through paracrine regulation of VICs. These novel findings raise the exciting possibility 
that currently available DPP-4 inhibitors might mitigate aortic stenosis, an issue ripe for formal 
investigation.
Therapeutic horizons for medical modification of fibrocalcific aortic valve disease
Pharmacologic modification of valvular heart disease has lagged behind other aspects of 
cardiovascular medicine. Strong association between lipids and CAVD led to trials of statins in 
treatment of CAVD. SEAS (the Simvastatin and Ezetimibe in Aortic Stenosis trial) and other 
clinical studies showed a lack of the therapeutic benefits of statins in CAVD and further 
emphasized the need to focus on valve-specific therapeutic targets.
14
The studies of Song et al.
13
indicate the need to evaluate DPP-4 inhibitors in this regard, and examine whether they have
adverse effects on bone metabolism or promote heart failure, the latter of particular concern in 
the CAVD population.
15
The recent advances in the mechanistic understanding of CAVD such as 
the provocative results with DPP-4 presented by Song et al. should reveal more novel targets for 
non-interventional approaches to modulating valve disease.
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Figure Legends:
Figure 1. Multifactorial mechanisms contribute to fibrocalcific aortic valve disease.
Figure 2. Structure of a normal and diseased aortic valve. (2A) A healthy aortic valve leaflet
contains VECs and quiescent fibroblast-like VICs, and three distinct extracellular matrix layers: 
a collagen-rich fibrosa, a glycosaminoglycan-enriched spongiosa, and an elastin-rich 
ventricularis. (2B) Disease progression involves VIC activation, recruitment of immune cells, 
and subsequent thickening and stiffening of the valve leaflets due to fibrosis and formation of 
calcific nodules that originate on the fibrosal surface of the leaflet. Histological staining of 
normal (C) and diseased (D) valve leaflets. Movat’s staining; collagen – yellow; proteoglycans –
blue-green; elastin and calcium – black. (C) Modified from Aikawa E. Circulation 2006.
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